RU2652880C2 - Антитело против рецептора эпидермального фактора роста - Google Patents

Антитело против рецептора эпидермального фактора роста Download PDF

Info

Publication number
RU2652880C2
RU2652880C2 RU2015147913A RU2015147913A RU2652880C2 RU 2652880 C2 RU2652880 C2 RU 2652880C2 RU 2015147913 A RU2015147913 A RU 2015147913A RU 2015147913 A RU2015147913 A RU 2015147913A RU 2652880 C2 RU2652880 C2 RU 2652880C2
Authority
RU
Russia
Prior art keywords
antibody
egfr
fragment
seq
light chain
Prior art date
Application number
RU2015147913A
Other languages
English (en)
Russian (ru)
Other versions
RU2015147913A (ru
Inventor
Цзе Лю
Чжобин ЧЖАН
Цзикуань ШАНЬ
Вэй СО
Original Assignee
Дженрикс (Шанхай) Байофармасертикал Ко., Лтд.
Байоэкс Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженрикс (Шанхай) Байофармасертикал Ко., Лтд., Байоэкс Терапьютикс Инк. filed Critical Дженрикс (Шанхай) Байофармасертикал Ко., Лтд.
Publication of RU2015147913A publication Critical patent/RU2015147913A/ru
Application granted granted Critical
Publication of RU2652880C2 publication Critical patent/RU2652880C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2015147913A 2013-04-07 2013-04-07 Антитело против рецептора эпидермального фактора роста RU2652880C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/073811 WO2014166029A1 (zh) 2013-04-07 2013-04-07 针对表皮生长因子受体的抗体

Publications (2)

Publication Number Publication Date
RU2015147913A RU2015147913A (ru) 2017-05-15
RU2652880C2 true RU2652880C2 (ru) 2018-05-03

Family

ID=51688811

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015147913A RU2652880C2 (ru) 2013-04-07 2013-04-07 Антитело против рецептора эпидермального фактора роста

Country Status (6)

Country Link
US (1) US9644031B2 (zh)
EP (1) EP2985292A4 (zh)
BR (1) BR112015025549A2 (zh)
RU (1) RU2652880C2 (zh)
WO (1) WO2014166029A1 (zh)
ZA (1) ZA201508035B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195993B (zh) 2016-02-06 2022-05-10 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
WO2020014098A1 (en) * 2018-07-09 2020-01-16 Shanghai Epimab Biotherapeutics Co., Ltd. Efficiently expressed egfr and pd-l1 bispecific binding proteins
WO2020084608A1 (en) * 2018-10-22 2020-04-30 Explore Bio 1 Ltd Precursor bispecific antibody constructs and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050433A2 (en) * 1997-05-05 1998-11-12 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20120328511A1 (en) * 2011-04-07 2012-12-27 Amgen Inc. Novel Antigen Binding Proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
DK1735348T3 (da) * 2004-03-19 2012-07-16 Imclone Llc Humant anti-epidermalt vækstfaktorreceptorantistof
DE602007011923D1 (de) * 2006-06-02 2011-02-24 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009149185A2 (en) * 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2010006060A2 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CA2772628A1 (en) * 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP6014596B2 (ja) * 2010-11-09 2016-10-25 メディミューン，エルエルシー 均一コンジュゲーションのための抗体足場
CN103172741B (zh) * 2011-12-20 2018-04-27 智翔（上海）医药科技有限公司 全人源抗egfr抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050433A2 (en) * 1997-05-05 1998-11-12 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20120328511A1 (en) * 2011-04-07 2012-12-27 Amgen Inc. Novel Antigen Binding Proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KABAT E.A. et al. Sequences of proteins of immunological interest. DIANE publishing, 5th ed., Vol.1, 1991, NIH Publication 91-3242, стр.103, 324. STEPLEWSKI ZENON et al. "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity", Proceedings of the National Academy of Sciences, 1988, 85:4852-4856. SCHNEIDER-MERCK T. et al. "Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage." The journal of immunology, 2010, 184(1): 512-520. ТРЯКИН А.А. "Таргетная терапия колоректального рака, рака желудка и поджелудочной железы." Практическая онкология, 2010, 11(3): 143-150. *

Also Published As

Publication number Publication date
WO2014166029A1 (zh) 2014-10-16
BR112015025549A2 (pt) 2017-10-10
RU2015147913A (ru) 2017-05-15
EP2985292A1 (en) 2016-02-17
US20160017045A1 (en) 2016-01-21
ZA201508035B (en) 2018-05-30
US9644031B2 (en) 2017-05-09
EP2985292A4 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
JP7374995B2 (ja) 抗ｐｄ－１／抗ｖｅｇｆａ二官能性抗体、その医薬組成物およびその使用
US20220002418A1 (en) Anti-pd-l1/vegf bifunctional antibody and use thereof
WO2017148424A1 (zh) 一种pdl-1抗体、其药物组合物及其用途
JP6033783B2 (ja) Ｐａｎ−ｈｅｒ抗体組成物
KR20210009308A (ko) 인간 넥틴4에 특이적인 항체
JP7102670B2 (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP2017506217A (ja) 標的ＴＧＦβ阻害
JP2023538945A (ja) 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
EP3099713B1 (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
WO2022017428A1 (zh) 抗ctla-4抗体及其用途
US20230312738A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
JP2022541022A (ja) 抗ｔｉｇｉｔ抗体及びその適用
JP2024504124A (ja) 新規の抗グレムリン１抗体
KR20180068982A (ko) 혈관신생 인자에 대한 매우 강력한 모노클로날 항체
US9644031B2 (en) Epidermal growth factor receptor antibody
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
US20240002530A1 (en) Anti-psma antibodies and methods of use
CN103172741B (zh) 全人源抗egfr抗体
US20230257465A1 (en) ANTI-PDL1 x EGFR BISPECIFIC ANTIBODY
JP2023550673A (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
JP2023533042A (ja) Ｉｌ－１２及び抗ｆａｐ抗体を含む融合タンパク質、並びにその使用
KR20130057959A (ko) 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
JP7371093B2 (ja) 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ
CN116333125A (zh) 结合死亡受体4和死亡受体5的抗体
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210408